Ytterbium 10-carboxyperylene-3,4,9-tricarboxylates for targeted NIR luminescent bioimaging.

Two new ytterbium coordination compounds Yb(HPTC)(H2O)2 (Yb1) and Yb(HPTC)(Phen) (Yb2) were obtained using 10-carboxyperylene-3,4,9-tricarboxylate ion (HPTC3-) as a sensitizer. Both coordination compounds exhibited intense NIR-II luminescence upon excitation in the visible range and formed stable suspensions with nanoparticles of 50-70 nm in size in an aqueous solution of sodium alginate. Both complexes demonstrated non-toxicity up to at least 25 mg L-1 in two cell cultures: cancer cells MCF7 and embryonic cells HEK293T - making them suitable for bioimaging. For both complexes, the accumulation in cells was directly measured and it was shown that the accumulation of Yb2 was the same for both cell types (0.51-0.52 πg per cell), while Yb1 demonstrated selective accumulation in cancer cells (0.04 πg per cell for HEK293T and 7.00 πg per cell for MCF7). Thus, Yb1 can also be proposed as a selective vis-excited NIR emitting bioprobe.

Liposomal form of 2-alkylthioimidazolone-based copper complexes for combined cancer therapy.

Aim: To develop an optimized approach for encapsulating a 2-alkylthioimidazolone-based copper coordination compound within liposomes, which could offer treatment of cancer and bacterial infections by reactive oxygen species generation toxicity mechanisms. Materials & methods: For drug-loaded liposome preparation, lipids and drug mixture in organic solvents was injected into copper salt solution, forming a coordination compound simultaneously embedded in the lipid bilayer. In vitro tests were performed on MCF7 and MDA-MB-231 breast cancer cells. Results: Liposomes had a loading capacity of up to 1.75% (molar drug-to-lipid ratio). In vitro tests showed increased viability and accumulation of the liposomal formulation compared with free drug as well as lack of cytotoxicity in hepatocytes. Conclusion: This optimized technique for encapsulating large copper complexes in liposomes could be used to improve their delivery and better treat cancer and bacterial infections.

This work introduces a new technique for copper-containing drugs encapsulation in a drug-delivery system. The drug, a promising copper compound, is embedded in lipid nanovesicles ­ tiny fat particles ­ for intravenous injection. In addition to chemical characterization of the obtained drug form, tests on cancer cells showed a noticeable effect, whereas healthy cell types were not harmed. Copper possesses not only anticancer effects but also antimicrobial properties, which are also shown by the drug form, and a test of combined suppression of cancer cell lines and bacteria was successful. Hence, the obtained drug form has the potential for dual treatment of cancer and bacterial infections.